BRENTWOOD, Tenn. / Sep 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it has successfully amended and extended its $777.5 million Term Loan Facility. The new terms reduce the applicable interest rate by 50 basis points from Term Secured Overnight Financing Rate (SOFR) plus 2.75% to Term SOFR plus 2.25%. The transaction extends the maturity of the facility to September 2032.
“This transaction enhances our financial flexibility and strengthens our capital position, allowing Ardent to continue investing in our communities while pursuing strategic growth,” said Ardent Health Chief Financial Officer Alfred Lumsdaine. “We appreciate the support of our lending partners and their continued confidence in our leadership and long-term growth strategy.”
The amended credit agreement is expected to reduce Ardent’s interest expense by approximately $3.9 million annually.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$14.59 |
Daily Change: | 0.09 0.62 |
Daily Volume: | 253,369 |
Market Cap: | US$2.090B |
August 05, 2025 May 06, 2025 March 31, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load